» Articles » PMID: 27403269

Tuberculosis 2015: Burden, Challenges and Strategy for Control and Elimination

Overview
Journal Infect Dis Rep
Publisher MDPI
Date 2016 Jul 13
PMID 27403269
Citations 101
Authors
Affiliations
Soon will be listed here.
Abstract

Tuberculosis (TB) is a leading cause of morbidity and mortality worldwide, accounting for about 9.6 million new cases and 1.5 million deaths annually. The poorest and socially excluded groups carry the largest burden of disease, which makes it essential to properly address the social determinants of health through poverty reduction measures and targeted interventions on high-risk populations. The spread of multidrug-resistance TB requires special attention and highlights the need to foster research on TB diagnostics, new drugs and vaccines. Although many advances have been made in the fight against TB over the last twenty years, a lot is still needed to achieve global elimination. The new end-TB strategy that was first launched in 2014 by the World Health Organization, is fully in line with the seventeen Sustainable Development Goals that came into effect since January 2016 and sets ambitious goals for the post-2015 agenda. A 90% reduction in TB-related mortality and an 80% decline in TB incidence within 2030 as well as the abolition of catastrophic expenditures for TB-affected people are the main targets of this strategy. Strong government commitment and adequate financing from all countries together with community engagement and appropriate investments in research are necessary in order to reach these objectives.

Citing Articles

Exploring socio-economic dimensions in HIV research: a comprehensive bibliometric analysis (1992-2024).

Yermukhanova L, Kuzembayev M, Salkhanova A, Narymbayeva N, Tazhiyeva A, Makhanbetkulova D Glob Health Action. 2025; 18(1):2474787.

PMID: 40071324 PMC: 11905308. DOI: 10.1080/16549716.2025.2474787.


Risk factors for multidrug resistance in pulmonary tuberculosis patients with diabetes mellitus.

Wu L, Chen N, Xia D, Jiang X Front Med (Lausanne). 2025; 12:1516207.

PMID: 39958828 PMC: 11825338. DOI: 10.3389/fmed.2025.1516207.


Spinal Cord Injury From Tuberculous Spondylitis Misdiagnosed as Metastatic Spinal Tumor and Bacterial Spondylitis: A Case Report & Literature Review.

Wui S, Ko M, Lee B, Lee S, Kwon W Korean J Neurotrauma. 2025; 20(4):246-251.

PMID: 39803336 PMC: 11711030. DOI: 10.13004/kjnt.2024.20.e41.


High Schistosoma mansoni Co-Infection in Tuberculosis Patients with or without Human Immunodeficiency Virus: A Prospective Cohort Study.

Baya B, Diarra B, Dabitao D, Somboro A, Traore F, Goita D Res Sq. 2024; .

PMID: 39281870 PMC: 11398560. DOI: 10.21203/rs.3.rs-4796634/v1.


Using a Knowledge and Awareness Survey to Engage and Inform a Community-Based Tuberculosis Intervention among Nomads in Adamawa State, Nigeria.

John S, Abdulkarim S, Katlholo T, Smyth C, Basason H, Rahman M Trop Med Infect Dis. 2024; 9(8).

PMID: 39195605 PMC: 11359801. DOI: 10.3390/tropicalmed9080167.


References
1.
Sotgiu G, Pontali E, Centis R, DAmbrosio L, Migliori G . Delamanid (OPC-67683) for treatment of multi-drug-resistant tuberculosis. Expert Rev Anti Infect Ther. 2015; 13(3):305-15. DOI: 10.1586/14787210.2015.1011127. View

2.
Evangelopoulos D, McHugh T . Improving the tuberculosis drug development pipeline. Chem Biol Drug Des. 2015; 86(5):951-60. DOI: 10.1111/cbdd.12549. View

3.
Lomazzi M, Borisch B, Laaser U . The Millennium Development Goals: experiences, achievements and what's next. Glob Health Action. 2014; 7:23695. PMC: 3926985. DOI: 10.3402/gha.v7.23695. View

4.
Herbert N, George A, Baroness Masham of Ilton , Sharma V, Oliver M, Oxley A . World TB Day 2014: finding the missing 3 million. Lancet. 2014; 383(9922):1016-8. DOI: 10.1016/S0140-6736(14)60422-0. View

5.
Gupta S, Granich R, Date A, Lepere P, Hersh B, Gouws E . Review of policy and status of implementation of collaborative HIV-TB activities in 23 high-burden countries. Int J Tuberc Lung Dis. 2014; 18(10):1149-58. DOI: 10.5588/ijtld.13.0889. View